This systematic review examines glutamatergic biomarkers in autism spectrum disorder and schizophrenia spectrum disorders, suggesting distinct neurochemical signatures exist.
Key Points
Shared and distinct glutamatergic alterations identified across schizophrenia spectrum disorders and autism spectrum disorder, with potential stage-specific patterns.
Analysis incorporates 1 H-MRS data from the dorsolateral prefrontal cortex and hippocampus, focusing on regional differences in metabolite concentrations.
Systematic review design will assess risk of bias using AXIS and MRS-Q, ensuring comprehensive quality evaluation.
Translational research aims to improve understanding of neurochemical differences, proposing pivotal biomarkers for diagnosis.